The End of the Beginning: The Evolving Landscape of Alzheimer’s Disease Pharmacotherapy

The Alzheimer’s disease market is forecast to grow from approximately $0.2 billion in 2023 to $7.8 billion in 2030. After decades of setbacks, this field appears to be at a pivotal point, with multiple novel therapies set to reshape the treatment landscape in the coming years. However, past challenges and regulatory hurdles have highlighted the need for more comprehensive solutions and ongoing innovation.

The field is moving towards earlier diagnosis and intervention, while also exploring promising research pathways beyond anti-amyloid and tau-targeting approaches. Continued investment across a range of modalities will be critical, as will the incorporation of novel biomarkers and imaging tools to enable precision medicine.

Download our latest whitepaper exploring the past, present, and future of Alzheimer’s disease pharmacotherapy.